April 28 Spring Bank Pharmaceuticals Inc
* Spring Bank Pharmaceuticals provides corporate update and reports first quarter 2017 financial and operational results
* Q1 loss per share $0.69
* Spring Bank Pharmaceuticals Inc - cash, cash equivalents and marketable securities were $21.1 million as of March 31, 2017
* Spring Bank Pharma - anticipates existing cash, cash equivalents will enable it to fund operating expenses and capex requirements into Q3 of 2018
* Spring Bank Pharmaceuticals - remains on track and anticipates reporting top-line results from SB 9200 25mg monotherapy dosing cohort in Q2 of 2017 Source text for Eikon: Further company coverage:
Watchdog group sues EPA to access communications with Icahn
WASHINGTON, June 27 A U.S. watchdog group filed a lawsuit in a federal court on Tuesday to force the Environmental Protection Agency to release communications with billionaire investor Carl Icahn, who it says tried to influence biofuels policy for personal gain.